As announced previously, the offering consists of units of common stocks and warrants, with each unit consisting of one share of common stock and a warrant to buy 0.3 of a share of common stock. Each unit will be sold for a purchase price of $3.00. Warrants to purchase additional shares will be exercisable at a price of $3.75 per share starting six months after issuance and will expire five years from the initial exercisable date of the warrants. It is anticipated that the offering’s closing will still take place on or around Sept. 23, subject to the satisfaction of customary closing conditions.
H.C. Wainwright & Co. LLC served as exclusive placement agent for the offering.
A shelf registration statement relating to the shares issued in this offering (File No. 333-185657) has been filed with and declared effective by the Securities and Exchange Commission. Agenus will file a prospectus supplement with the SEC relating to the offering. Copies of the prospectus supplement and accompanying prospectus can be accessed at www.sec.gov or received by request from H.C. Wainwright & Co., placements@hcwco.com, or by mail from Agenus, Inc., 3 Forbes Rd., Lexington, Mass. 02421.
For more information about Agenus, visit www.agenusbio.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html
No comments:
Post a Comment